Adagene
Price & Volume
Stats
See more52W Range | $1.30-$4.75 |
Market Cap | $264.2M |
Shares Short | 814,328 |
Financials
See moreRevenue (12 Mos) | $7.6M |
Revenue Growth (YoY) | 7,332.8% |
Gross Profit (12 Mos) | $7.6M |
Diluted EPS | -$0.38 |
News
See moreYahoo Finance • last month
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Yahoo Finance • 2 months ago
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Yahoo Finance • 2 months ago
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
Yahoo Finance • 2 months ago
Adagene ADR Non-GAAP EPS of -$0.24 beats by $0.41, revenue of $7.7M beats by $6.03M
About
CEO | Dr. Peter P. Luo Ph.D. |
CFO | Mr. Man Kin Tam M.B.A. |
Address | Building C14, Suzhou, China, 215123 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 128 |